geranylgeraniol has been researched along with cyclin d1 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dutta, D; Elfakhani, M; Fernandes, NV; Hynds, DL; Katuru, R; King, C; Mills, N; Mo, H | 1 |
| Fukushima, S; Minegaki, T; Morioka, C; Nishiguchi, K; Takanashi, H; Tsuji, S; Tsujimoto, M; Uno, J; Watanabe, A; Yamamoto, S | 1 |
2 other study(ies) available for geranylgeraniol and cyclin d1
| Article | Year |
|---|---|
Mevalonate depletion mediates the suppressive impact of geranylgeraniol on murine B16 melanoma cells.
Topics: 3T3-L1 Cells; Alkaline Phosphatase; Animals; Apoptosis; Cell Cycle; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase 4; Diterpenes; Humans; Lovastatin; Melanoma, Experimental; Mevalonic Acid; Mice; Vitamin E | 2011 |
Effects of bisphosphonates on human esophageal squamous cell carcinoma cell survival.
Topics: Annexins; Apoptosis; Bone Density Conservation Agents; Carcinoma, Squamous Cell; Caspase 3; Caspase 7; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Cyclin D1; Diphosphonates; Diterpenes; Drug Screening Assays, Antitumor; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Farnesol; G1 Phase Cell Cycle Checkpoints; Humans; Squalene | 2016 |